肝硬化对68Ga-FAPI PET/CT在肝内肿瘤中的影响
本二次分析纳入39例肝硬化患者与48例无肝硬化患者,评估肝硬化对肝实质及肝内肿瘤68Ga-FAPI摄取的影响。无肝内肿瘤者肝硬化组肝68Ga-FAPI SUVavg为1.42,高于无肝硬化组的0.45(P=0.002);肝内肿瘤诊断敏感度两组分别为98%与93%。肝硬化患者中68Ga-FAPI对肝内肿瘤的敏感度高于18F-FDG(98% vs 41%),肿瘤SUVmax也更高(2.60 vs 6.68,P<0.001)。
要点
- 肝硬化可致背景肝68Ga-FAPI摄取增高,无肝内肿瘤者肝硬化组肝SUVavg为1.42,高于无肝硬化组的0.45。
- 肝硬化患者中68Ga-FAPI诊断肝内肿瘤敏感度为98%,高于18F-FDG的41%。
- 肝硬化患者肝内肿瘤68Ga-FAPI SUVmax中位2.60,18F-FDG为6.68(P<0.001)。
核心结论
- 68Ga-FAPI诊断肝内肿瘤的敏感度不受肝硬化影响,且在肝硬化患者中诊断准确性高于18F-FDG。
研究设计与样本
- 前瞻性试验的二次分析,纳入2020年8月至2022年5月间行68Ga-FAPI和18F-FDG PET/CT或仅行68Ga-FAPI PET/CT的患者,肝硬化组39例(中位年龄58岁,IQR 50-68;男29例;肝内肿瘤24个),无肝硬化组48例(中位年龄59岁,IQR 51-67;男30例;肝内肿瘤23个),肝硬化患者经影像与临床综合评估选取,无肝硬化患者随机选取,由两名放射科医师测量。
诊断标准与关键数值
- 无肝内肿瘤者肝硬化组肝68Ga-FAPI SUVavg中位1.42(IQR 0.55-2.85),无肝硬化组0.45(IQR 0.41-0.72),P=0.002;肝内肿瘤诊断敏感度肝硬化组98% vs 无肝硬化组93%;肝硬化患者中68Ga-FAPI vs 18F-FDG诊断肝内肿瘤敏感度98% vs 41%;肿瘤SUVmax中位68Ga-FAPI 2.60(IQR 2.14-4.49)vs 18F-FDG 6.68(IQR 4.65-10.08),P<0.001。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Gallium 68 (68Ga)-labeled fibroblast activation protein inhibitor (FAPI) is of great diagnostic value for intrahepatic tumors. However, cirrhosis may lead to increased 68Ga-FAPI uptake in background liver, affecting the diagnostic ability of 68Ga-FAPI. Purpose To assess the effect of cirrhosis on liver parenchyma and intrahepatic tumor uptake of 68Ga-FAPI and to compare the ability of 68Ga-FAPI and fluorine 18 (18F)-labeled fluorodeoxyglucose (FDG) PET/CT to depict intrahepatic tumors in patients with cirrhosis. Materials and Methods In this secondary analysis of a prospective trial, patients who underwent both 68Ga-FAPI and 18F-FDG PET/CT and those who underwent only 68Ga-FAPI PET/CT between August 2020 and May 2022 were considered for inclusion in the cirrhotic or noncirrhotic group, respectively. Patients with cirrhosis were chosen via a comprehensive assessment of imaging and clinical data, and patients without cirrhosis were randomly selected. 68Ga-FAPI and 18F-FDG PET/CT data were measured by two radiologists. Between-groups and within-group data were tested with the Mann-Whitney U test and the Wilcoxon signed-rank test, respectively. Results A total of 39 patients with cirrhosis (median age, 58 years [IQR, 50-68]; 29 male; 24 intrahepatic tumors) and 48 patients without cirrhosis (median age, 59 years [IQR, 51-67]; 30 male; 23 intrahepatic tumors) were evaluated. In patients without intrahepatic tumors, the liver 68Ga-FAPI average standardized uptake value (SUVavg) was higher in the cirrhotic group than in the noncirrhotic group (median SUVavg, 1.42 [IQR, 0.55-2.85] vs 0.45 [IQR, 0.41-0.72]; P = .002). However, no difference was observed in the diagnosis of intrahepatic tumor sensitivity (98% vs 93%, respectively). When compared with 18F-FDG, the sensitivity of 68Ga-FAPI PET/CT in the detection of intrahepatic tumors in patients with cirrhosis (41% vs 98%, respectively) and maximum standardized uptake value of tumors (median SUVmax, 2.60 [IQR, 2.14-4.49] vs 6.68 [IQR, 4.65-10.08]; P < .001) were higher. Conclusion The sensitivity of 68Ga-FAPI in the diagnosis of intrahepatic tumors was not affected by cirrhosis, and diagnostic accuracy of 68Ga-FAPI was higher than that of 18F-FDG in patients with cirrhosis. © RSNA, 2023 Supplemental material is available for this article.
引用
- Peng, Cao, Guo, et al. Influence of Cirrhosis on 68Ga-FAPI PET/CT in Intrahepatic Tumors. Radiology. 2023. PMID: 37219440. doi:10.1148/radiol.222448
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。